MolMed, clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases, announced that the German public health insurance system (GKV) has approved the reimbursement of Zalmoxis® at a price of 130,000 Euros per infusion (ex-factory price excluding VAT).
The cost per patient will be based on the approved dosing schedule, which allows from 1 to 4 infusions, until the immune-reconstitution is reached, and on the clinical experience, that shows an average of just over 2 infusions per patient.
The agreement will be in force as of February 15th, 2019 and follows the authorization granted in February 2018 and the consequent drug evaluation and price negotiation process regulated by the AMNOG system, according to which the G-BA Federal Committee recognized to MolMed’s therapy a benefit for the treatment of adult patients with high risk relapse leukemia in haplo-identical haematopoietic stem cell transplantation (haplo-HSCT).
Thanks to this agreement, valid for the next 24 months, Zalmoxis® could be prescribed not only in the 2 transplant centres authorized hitherto, but in all the bone marrow transplant centres operating in Germany.
For more info: https://www.molmed.com/sites/default/files/uploads/press-releases/3501/3501_1549308621.pdf